A pivotal Phase 2b study of Betalutin in patients with relapsed 3rd line anti-CD 20 Ab-refractory Follicular Lymphoma
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2017
At a glance
- Drugs Lutetium-(177lu) lilotomab satetraxetan (Primary)
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms PARADIGME
- Sponsors Nordic Nanovector
- 28 Nov 2017 New trial record
- 22 Nov 2017 According to a Nordic Nanovector media release, the company anticipates data read-out and first submission for marketing approval in the second half of 2019.
- 22 Nov 2017 According to a Nordic Nanovector media release, the company has submitted protocol amendment to regulatory authorities and subjects to approval patient screening anticipated before end of 2017.